Migraine affects more than one billion individuals each year across the world, and is one of
the most common neurologic disorders, with a high prevalence and morbidity, especially …

Epidemiology, the study of diseases in populations, is essential to our understanding of
every aspect of migraine. Migraine epidemiology informs clinical care of patients, shapes …

Importance Ubrogepant is an oral calcitonin gene–related peptide receptor antagonist under
investigation for acute treatment of migraine. Objective To evaluate the efficacy and …

Background Migraine is a common and often debilitating neurological disease. It can be
divided into episodic and chronic subforms based on the number of monthly headache days …

Objective To study the weighted average global prevalence of migraine at the community
level. Study design and setting A systematic review using advanced search strategies …

Background Quality clinical trials form an essential part of the evidence base for the
treatment of headache disorders. In 1991, the International Headache Society Clinical Trials …

Clinical trials are a key component of the evidence base for the treatment of headache
disorders. In 1991, the International Headache Society Clinical Trials Standing Committee …

This revision of the 2005 British Association for Psychopharmacology guidelines for the
evidence-based pharmacological treatment of anxiety disorders provides an update on key …

Background Anxiety and mood disorders have been shown to be the most relevant
psychiatric comorbidities associated with migraine, influencing its clinical course, treatment …

Background Benefits of calcitonin-gene related peptide (CGRP) inhibition have not been
established in chronic migraine. Here we assess the safety, tolerability, and efficacy of two …